Subtopic Deep Dive
Indomethacin Prophylaxis for Patent Ductus Arteriosus
Research Guide
What is Indomethacin Prophylaxis for Patent Ductus Arteriosus?
Indomethacin prophylaxis for patent ductus arteriosus (PDA) involves early intravenous administration of indomethacin to preterm infants to prevent PDA development and reduce complications like intraventricular hemorrhage.
This approach targets preterm infants under 29 weeks gestation where PDA occurs in 40-55% of cases (McNamara and Sehgal, 2007). Prophylactic indomethacin reduces symptomatic PDA, surgical ligation needs, and severe intraventricular hemorrhage but shows no mortality benefit (Fowlie et al., 2010; 481 citations). Over 10 systematic reviews and RCTs from 2003-2020 evaluate dosing, echocardiography efficacy, and short-term outcomes.
Why It Matters
Indomethacin prophylaxis lowers NICU surgical interventions for PDA, improving preterm infant survival and reducing intraventricular hemorrhage rates (Fowlie et al., 2010). It guides clinical decisions in neonatal care, balancing short-term PDA closure gains against long-term neurodevelopmental risks debated in reviews (Bose and Laughon, 2007). Mitra et al. (2018; 309 citations) compared indomethacin to alternatives like ibuprofen, influencing treatment guidelines to minimize bronchopulmonary dysplasia in global NICUs.
Key Research Challenges
Long-term Neurodevelopmental Effects
Prophylactic indomethacin reduces short-term PDA but lacks evidence on mortality or long-term outcomes like cerebral palsy (Fowlie et al., 2010). Studies show potential risks without clear benefits beyond infancy (Fowlie and Davis, 2003). RCTs need extended follow-up to assess brain injury impacts.
Optimal Dosing Regimens
Standard three-dose indomethacin protocols require tailoring for infants under 1000g, with variable echocardiography responses (Hermes-DeSantis and Clyman, 2006). Comparisons to ibuprofen or acetaminophen reveal inconsistent closure rates (Mitra et al., 2018). Personalized regimens based on ductal staging remain unstandardized (McNamara and Sehgal, 2007).
Prophylactic vs Targeted Treatment
Debate persists on universal prophylaxis versus treating symptomatic PDA only, due to overtreatment risks in low-risk infants (Bose and Laughon, 2007). Surgical ligation outcomes post-medical failure show impaired ventricular function (McNamara et al., 2010). Evidence gaps hinder consensus on initial approaches (Malviya et al., 2013).
Essential Papers
Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants
Peter W Fowlie, Peter G. Davis, William McGuire · 2010 · Cochrane Database of Systematic Reviews · 481 citations
Prophylactic indomethacin has short-term benefits for preterm infants including a reduction in the incidence of symptomatic PDA, PDA surgical ligation, and severe intraventricular haemorrhage. Howe...
Towards rational management of the patent ductus arteriosus: the need for disease staging: Table 1
Patrick J. McNamara, Arvind Sehgal · 2007 · Archives of Disease in Childhood Fetal & Neonatal · 365 citations
Perspective on the review by Bose and Laughon (see page 498) Patent ductus arteriosus (PDA) is common problem, with rates of 40–55% in babies born less than 29 weeks’ gestation,1 2 yet decisions ...
Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants
Souvik Mitra, Iván D. Flórez, María Tamayo et al. · 2018 · JAMA · 309 citations
PROSPERO Identifier: CRD42015015797.
Patent Ductus Arteriosus of the Preterm Infant
Shannon E. G. Hamrick, Hannes Sallmon, Allison T. Rose et al. · 2020 · PEDIATRICS · 266 citations
Postnatal ductal closure is stimulated by rising oxygen tension and withdrawal of vasodilatory mediators (prostaglandins, nitric oxide, adenosine) and by vasoconstrictors (endothelin-1, catecholami...
Patent ductus arteriosus: lack of evidence for common treatments
Cameron Bose, M. M Laughon · 2007 · Archives of Disease in Childhood Fetal & Neonatal · 198 citations
Patent ductus arteriosus (PDA) is a common diagnosis among extremely premature infants, especially in those with lung disease. Treatments are often used to close the PDA. Despite nearly three decad...
Patent ductus arteriosus: pathophysiology and management
Evelyn R. Hermes‐DeSantis, Ronald I. Clyman · 2006 · Journal of Perinatology · 190 citations
Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants
Manoj N Malviya, Arne Ohlsson, Sachin S Shah · 2013 · Cochrane Database of Systematic Reviews · 184 citations
There are insufficient data to conclude whether surgical ligation or medical treatment with indomethacin is preferred as the initial treatment for symptomatic PDA in preterm infants.
Reading Guide
Foundational Papers
Start with Fowlie et al. (2010; 481 citations) for prophylactic efficacy evidence; McNamara and Sehgal (2007; 365 citations) for PDA staging rationale; Hermes-DeSantis and Clyman (2006) for pathophysiology basics.
Recent Advances
Study Hamrick et al. (2020; 266 citations) for ductal closure mechanisms; Mitra et al. (2018; 309 citations) for treatment network meta-analysis.
Core Methods
Core techniques include RCTs with echocardiography for hemodynamic significance, Cox inhibitor dosing (indomethacin 0.1-0.2 mg/kg), and composite outcomes like death or hemorrhage (Fowlie et al., 2010).
How PapersFlow Helps You Research Indomethacin Prophylaxis for Patent Ductus Arteriosus
Discover & Search
Research Agent uses searchPapers and citationGraph on Fowlie et al. (2010; 481 citations) to map 50+ related RCTs and Cochrane reviews, revealing prophylaxis vs. targeted treatment clusters. exaSearch uncovers echocardiography dosing studies; findSimilarPapers links McNamara and Sehgal (2007) to staging frameworks.
Analyze & Verify
Analysis Agent applies readPaperContent to extract hazard ratios from Fowlie et al. (2010), then verifyResponse with CoVe for hallucination checks on PDA closure rates. runPythonAnalysis performs meta-analysis on intraventricular hemorrhage data via pandas, with GRADE grading for evidence quality on short-term outcomes.
Synthesize & Write
Synthesis Agent detects gaps in long-term data from Bose and Laughon (2007), flags contradictions between prophylactic benefits and surgical risks (McNamara et al., 2010). Writing Agent uses latexEditText, latexSyncCitations for Fowlie et al., and latexCompile to generate review manuscripts; exportMermaid diagrams ductal pathophysiology pathways.
Use Cases
"Run meta-analysis on indomethacin prophylaxis intraventricular hemorrhage rates from Cochrane reviews."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas forest plots on Fowlie et al. 2010 data) → researcher gets GRADE-assessed RR estimates with CIs.
"Draft LaTeX review comparing indomethacin to ibuprofen for preterm PDA closure."
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Mitra et al. 2018) + latexCompile → researcher gets compiled PDF with synced references.
"Find code for PDA echocardiography analysis in neonatal RCTs."
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets R scripts for ductal flow quantification from similar papers.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ papers starting with citationGraph on Fowlie et al. (2010), producing structured reports with GRADE tables on prophylaxis efficacy. DeepScan applies 7-step analysis with CoVe checkpoints to Mitra et al. (2018), verifying closure associations. Theorizer generates hypotheses on ductal staging from McNamara and Sehgal (2007) literature synthesis.
Frequently Asked Questions
What is indomethacin prophylaxis for PDA?
Early intravenous indomethacin given within 24 hours of birth to preterm infants prevents PDA and intraventricular hemorrhage (Fowlie et al., 2010).
What are the main methods studied?
RCTs compare three-dose indomethacin regimens to placebo, ibuprofen, or expectant management, assessing echocardiography closure and short-term outcomes (Mitra et al., 2018; Fowlie and Davis, 2003).
What are the key papers?
Fowlie et al. (2010; 481 citations) is the top Cochrane review; McNamara and Sehgal (2007; 365 citations) proposes disease staging; Mitra et al. (2018; 309 citations) networks treatments.
What open problems remain?
Long-term neurodevelopment effects unclear; optimal prophylaxis criteria undefined; surgical vs. medical trade-offs unproven (Bose and Laughon, 2007; Malviya et al., 2013).
Research Cardiovascular Conditions and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Indomethacin Prophylaxis for Patent Ductus Arteriosus with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers